Navigation Links
DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
Date:9/29/2008

GRONINGEN and LEIDEN, Netherlands and PARSIPPANY, N.J., Sept. 29 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that the high-titer fed-batch process developed at the PERCIVIA PER.C6(R) Development Center, their joint venture in Cambridge, USA was recently scaled up to 250 liters by DSM Biologics scientists at their GMP facility in Groningen, The Netherlands. They successfully achieved 8 grams per liter for an IgG expressed by PER.C6(R) cells using chemically defined cell culture medium in a SUB (single-use bioreactor).

This result confirms a reliable, versatile and commercially feasible production platform to manufacture large amounts of therapeutic proteins with ease and economic affordability. Also, this latest result, using conventional fed-batch process, adds to the previous achievements of 27 grams per liter -- biomass corrected -- using DSM's XD(TM) technology, and demonstrating a reliable performance of the PER.C6(R) cell line under such production conditions.

Marco Cacciuttolo, CEO and President of PERCIVIA, comments that, "This new development further strengthens our commitment to modernize therapeutic protein manufacturing. The successful scale up of the high-titer fed-batch process means that the PER.C6(R) platform can be easily and quickly implemented into commercial facilities with no retrofit requirements. We continue to be very pleased and enthused by the ease of use, the reproducibility, and the overall robustness of the platform."

About PER.C6(R) Technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About XD(TM) techn
'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
2. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
3. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
4. HYSTA Announces Dr. Qi Lu to continue on as President of HYSTA, USA
5. Wyeth Announces Increase in Common Stock Dividend
6. Telik Announces Receipt of Nasdaq Notice
7. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
8. Vermillion Announces Receipt of NASDAQ Panel Decision
9. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
10. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
11. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... MO (PRWEB) , ... August 26, 2015 , ... ... it is increasing its investment in the development and manufacture of highly valued ... The company’s scientific team's extensive expertise with protein chemistry has led to ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... ("MO2"), an entity wholly owned by Mr. Yuen Kam, ... has acquired the outstanding shares (the "Shares") of  Excellent ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... WASHINGTON, June 11 Syngenta today ... to add an innovative antitoxin crop protection technology to the ... which is aimed at reducing aflatoxin, a toxin that can ... heat and drought stress. , , "The acquisition ...
... PharmaNet Development Group, Inc., a leading provider of clinical development services ... its participation at several international professional meetings during the month of June. ... 45th Drug Information Association (DIA) Annual Meeting, ... 321, ...
... Study to Evaluate FDA-Approved Topical Anesthetic Pretreatment , ... Inc. (Nasdaq: NGSX ) announced today that ... its proposed study to evaluate Qutenza(TM) in patients with ... anesthetic. As part of its ongoing new drug application ...
Cached Biology Technology:Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 2Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 3PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June 2NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 2NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 3NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 4
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... This release is available in German . ... in many animal species. During mating season male testosterone ... and masculine features. Male bonobos, however, invest much more ... levels would collide with this increased tendency towards forming ...
... PROVIDENCE, R.I. [Brown University] For the 26 million ... way to check glucose levels. It is invasive and ... working on a new sensor that can check blood ... The technique takes advantage of a convergence of ...
... Spanish . There are some jobs ("dirty ... a certain amount of social rejection towards the people who ... to moral conflicts and ethical decisions related to performing those ... perspective, as in the case of a police officer who ...
Cached Biology News:Bonobos' unusual success story 2Biochip measures glucose in saliva, not blood 2Biochip measures glucose in saliva, not blood 3Moral imagination as a key to overcoming work-related stigmas 2
Rat CNTF R alpha Affinity Purified Polyclonal Ab...
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
... NOS activity by monitoring the conversion of ... simple, sensitive, and specific for NOS activity ... and purified enzyme preparations. The kit includes ... reactions. Radiolabeled arginine and NADPH are not ...
Biology Products: